VisAcT (18F-AraG) Imaging in Solid Tumors
Advanced Solid Tumors
Phase 1/2Active
Key Facts
About CellSight Technologies
CellSight Technologies is a private, pre-revenue biotech focused on a diagnostic imaging platform for the immune system. Its core technology, the VisAcT (18F-AraG) PET tracer, selectively accumulates in activated T cells, providing a non-invasive window into immune activity. The company is actively advancing its platform through multiple investigator-sponsored clinical trials, primarily in non-small cell lung cancer (NSCLC), with the goal of guiding and improving immunotherapy outcomes. Its long-term vision extends to neurodegenerative and cardiac diseases where immune activation plays a key role.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |